Merlintrader
Nov 12, 7:29 PM
New on Merlintrader: the
$MIRM stock hub. Mirum's brelovitug met the primary endpoint in the Phase 3 AZURE-4 study in hepatitis delta (Nov 10). Q3 net product sales were 185.7 million dollars, with 500.5 million of cash and investments. Next: VANTAGE PBC topline in Q1 2027.
Full
$MIRM stock hub: https://www.merlintrader.com/mirum-pharmaceuticals-mirm-stock-hub/
Not investment advice.
0 replies